Synopsis
In the largest RCT of SCS for painful diabetic neuropathy (PDN), 216 patients with symptoms refractory to conventional treatments were randomized 1:1 to continue with conventional medical management (CMM) alone or add 10 kHz SCS to CMM. Outcomes are durable to 6-month follow-up with 5.4% (5/93) of CMM subjects as pain responders compared with 85.1% (74/87) of 10 kHz SCS+CMM subjects (p < 0.001). Investigators observed sensory improvements in 3.3% (3/92) of CMM subjects versus 61.9% (52/84) of 10 kHz SCS+CMM subjects (p < 0.001). This study provides Level I evidence for high frequency SCS to treat PDN patients with refractory symptoms.
Disclosure
Study funded by Nevro Corp.
Categories
- Clinical advancements in pain management,
- Bioelectronic medicine
Author(s):
- Dr. Erika A. Petersen, MD, Director of the Section of Functional and Restorative Neurosurgery, Department of Neurosurgery, University of Arkansas for Medical Sciences
- Dr. Thomas G. Stauss, MD, Co- Owner & Attending Physician, Advanced Pain Management
- Dr. James A. Scowcroft, MD, Pain Management Associates
- Dr. Judith L. White, MD, Medical Director, AES Compass Orlando
- Dr. Shawn M. Sills, MD, Medical Director, Touchstone Interventional Pain Center
- Dr. Kasra Amirdelfan, MD, Interventional Pain Management Physician, IPM Medical Group
- Dr. Maged N. Guirguis, MD, Division System Lead - Interventional Pain Management, Ochsner Health System
- Dr. Jijun Xu, MD, PhD, Pain Management Physician, Department of Pain Management, Cleveland Clinic Foundation
- Dr. Cong Yu, MD, Pain Medicine Physician, Swedish Health Services
- Ali Nairizi, MD, Nevada Advanced Pain Specialists
- Denis G. Patterson, DO, Nevada Advanced Pain Specialists
- Vincent Galan, MD, Pain Care
- Richard H. Bundschu, MD, Interventional Pain Management Specialist, Coastal Orthopedics and Sports Medicine
- Neel D. Mehta, MD, Department of Anesthesiology, Weill Cornell Medical College
- Dr. Dawood Sayed, MD, Department of Anesthesiology and Pain Medicine, University of Kansas Medical Center
- Dr. Shivanand P. Lad, MD, PhD, Department of Neurosurgery, Duke University
- David J. DiBenedetto, MD, Boston PainCare
- Khalid A. Sethi, MD, Department of Neurosurgery, United Health Services
- Dr. Paul W. Wu, MD, Interventional Physiatrist, Holy Cross Hospital
- Dr. Charles E. Argoff, MD, Department of Neurology, Albany Medical Center
- Christian E. Nasr, MD, Department of Endocrinology, Cleveland Clinic Foundation
- Rod S. Taylor, MSc, PhD, Institute of Health and Well Being, University of Glasgow
- Dr. David L. Caraway, MD, PhD, Chief Medical Officer, Nevro, Inc.
- Dr. Nagy A. Mekhail, MD, PhD, Carl Wasmuth Chair in Anesthesiology, Cleveland Clinic
Tags: Bioelectronic Medicine Interventional Pain Management Endocrinology
| Display Label | Action |
|---|---|
| Abstract - NPC2021 - Petersen - Sustained Benefits of 10 kHz Spinal Cord | Download Abstract |
| Poster - NPC2021 - Petersen - Sustained Benefits of 10 kHz Spinal Cord | Download Poster |
Please use this thread to discuss the following:
Sustained Benefits of 10kHz Spinal Cord Stimulation for Painful Diabetic Neuropathy-6-Month Randomized Controlled Trial Results
Synopsis
In the largest RCT of SCS for painful diabetic neuropathy (PDN), 216 patients with symptoms refractory to conventional treatments were randomized 1:1 to continue with conventional medical management (CMM) alone or add 10 kHz SCS to CMM. Outcomes are durable to 6-month follow-up with 5.4% (5/93) of CMM subjects as pain responders compared with 85.1% (74/87) of 10 kHz SCS+CMM subjects (p < 0.001). Investigators observed sensory improvements in 3.3% (3/92) of CMM subjects versus 61.9% (52/84) of 10 kHz SCS+CMM subjects (p < 0.001). This study provides Level I evidence for high frequency SCS to treat PDN patients with refractory symptoms.
Disclosure
Study funded by Nevro Corp.
Categories
1) Clinical advancements in pain management, 2) Bioelectronic medicine